However, EGFR mutations were observed in 10–20% of white patients (Dearden et al., 2013), translocations of ALK were identified in 2–7% of patients with NSCLC (Mesaros et al., 2014) and ROS1 in 1–2% of patients with NSCLC (Bergethon et al., 2012). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.